CureVac NV
NASDAQ:CVAC

Watchlist Manager
CureVac NV Logo
CureVac NV
NASDAQ:CVAC
Watchlist
Price: 2.99 USD 1.01% Market Closed
Market Cap: 670.7m USD
Have any thoughts about
CureVac NV?
Write Note

CureVac NV
Income from Continuing Operations

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

CureVac NV
Income from Continuing Operations Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Income from Continuing Operations CAGR 3Y CAGR 5Y CAGR 10Y
CureVac NV
NASDAQ:CVAC
Income from Continuing Operations
-€260.2m
CAGR 3-Years
-26%
CAGR 5-Years
-30%
CAGR 10-Years
N/A
BioNTech SE
NASDAQ:BNTX
Income from Continuing Operations
€930.3m
CAGR 3-Years
296%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
MorphoSys AG
XETRA:MOR
Income from Continuing Operations
-€456.3m
CAGR 3-Years
-37%
CAGR 5-Years
-50%
CAGR 10-Years
N/A
Immatics NV
NASDAQ:IMTX
Income from Continuing Operations
-€97m
CAGR 3-Years
23%
CAGR 5-Years
-25%
CAGR 10-Years
N/A
Biotest AG
XETRA:BIO
Income from Continuing Operations
€68.5m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
10%
Formycon AG
XETRA:FYB
Income from Continuing Operations
€75.8m
CAGR 3-Years
N/A
CAGR 5-Years
61%
CAGR 10-Years
N/A
No Stocks Found

CureVac NV
Glance View

Market Cap
670.8m USD
Industry
Biotechnology

CureVac BV is a clinical-stage biopharmaceutical company, which engages in developing transformative medicines based on messenger ribonucleic acid (mRNA). The company is headquartered in Tuebingen, Baden-Wuerttemberg and currently employs 500 full-time employees. The company went IPO on 2020-08-14. The firm is engaged in the therapeutic development of messenger Ribonucleic Acid (mRNA) and RNA-based vaccines. CureVac AG focuses on developing vaccines for infectious diseases and drugs to treat cancer and rare diseases. The firm's pipeline focuses on three areas: cancer immunotherapy, prophylactic vaccines, and protein-based therapies.

CVAC Intrinsic Value
4.32 USD
Undervaluation 31%
Intrinsic Value
Price

See Also

What is CureVac NV's Income from Continuing Operations?
Income from Continuing Operations
-260.2m EUR

Based on the financial report for Dec 31, 2023, CureVac NV's Income from Continuing Operations amounts to -260.2m EUR.

What is CureVac NV's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 5Y
-30%

Over the last year, the Income from Continuing Operations growth was -4%. The average annual Income from Continuing Operations growth rates for CureVac NV have been -26% over the past three years , -30% over the past five years .

Back to Top